The Oncolytic Virus Therapy Market is expanding as pharmaceutical companies and biotechnology researchers investigate virus-based approaches to cancer treatment. The market is expected to grow from approximately USD 3.0 billion in 2025 to USD 9.8 billion by 2035, supported by a projected 12.4% CAGR. 

Hospitals are an important end-user segment because they provide the infrastructure required to administer advanced cancer therapies and monitor patients during treatment. Specialized oncology centers can also support clinical adoption as therapies move through development.

Cancer research institutes play a critical role in advancing oncolytic virus technologies. These organizations conduct laboratory studies and clinical trials that help evaluate the effectiveness and safety of different viral platforms.

Outpatient clinics represent another emerging end-user category. As treatment protocols become more established, selected therapies may become accessible in outpatient settings, improving convenience for appropriate patients.

Intratumoral administration is gaining attention because it allows the therapeutic virus to be delivered directly into a tumor. Intravenous administration can provide systemic exposure and may be useful when treatment needs to reach tumors at multiple sites.

The continued development of administration technologies, clinical protocols, and patient-selection strategies is expected to support broader adoption of oncolytic virus therapies.